Portage Biotech (NASDAQ:PRTG) and Continental Resources (NYSE:CLR) Critical Survey

Continental Resources (NYSE:CLR – Get Rating) and Portage Biotech (NASDAQ:PRTG – Get Rating) are both oils/energy companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Insider & Institutional Ownership

13.4% of Continental Resources shares are held by institutional investors. Comparatively, 4.6% of Portage Biotech shares are held by institutional investors. 58.6% of Continental Resources shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Continental Resources has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Continental Resources and Portage Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Continental Resources	3	10	4	0	2.06
Portage Biotech	0	0	4	0	3.00

Continental Resources presently has a consensus price target of $69.29, suggesting a potential upside of 4.17%. Portage Biotech has a consensus price target of $33.25, suggesting a potential upside of 259.07%. Given Portage Biotech’s stronger consensus rating and higher probable upside, analysts plainly believe Portage Biotech is more favorable than Continental Resources.

Earnings & Valuation

This table compares Continental Resources and Portage Biotech’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Continental Resources	$5.72 billion	4.22	$1.66 billion	$8.05	8.26
Portage Biotech	N/A	N/A	-$15.83 million	($1.28)	-7.23

Continental Resources has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than Continental Resources, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Continental Resources and Portage Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Continental Resources	37.73%	40.32%	17.67%
Portage Biotech	N/A	-13.23%	-11.46%

Summary

Continental Resources beats Portage Biotech on 10 of the 12 factors compared between the two stocks.

About Continental Resources

(Get Rating)

Continental Resources, Inc. explores for, develops, produces, and manages crude oil, natural gas, and related products primarily in the north, south, and east regions of the United States. The company sells its crude oil and natural gas production to energy marketing companies, crude oil refining companies, and natural gas gathering and processing companies. As of December 31, 2021, its proved reserves were 1,645 million barrels of crude oil equivalent (MMBoe) with proved developed reserves of 908 MMBoe. The company was founded in 1967 and is headquartered in Oklahoma City, Oklahoma.

About Portage Biotech

(Get Rating)

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.